Alteplase at 0.6 mg/kg for Acute Ischemic Stroke Within 3 Hours of Onset

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Alteplase at 0.6 mg/kg for Acute Ischemic Stroke Within 3 Hours of Onset

Background and Purpose—Based on previous studies comparing different recombinant tissue plasminogen activator (rt-PA) doses, we performed a clinical trial with 0.6 mg/kg, which is lower than the internationally approved dosage of 0.9 mg/kg, aiming to assess the efficacy and safety of alteplase in acute ischemic stroke for the Japanese. Methods—Our prospective, multicenter, single-arm, open-labe...

متن کامل

Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT).

BACKGROUND AND PURPOSE Based on previous studies comparing different recombinant tissue plasminogen activator (rt-PA) doses, we performed a clinical trial with 0.6 mg/kg, which is lower than the internationally approved dosage of 0.9 mg/kg, aiming to assess the efficacy and safety of alteplase in acute ischemic stroke for the Japanese. METHODS Our prospective, multicenter, single-arm, open-la...

متن کامل

ATLANTIS trial: results for patients treated within 3 hours of stroke onset. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.

BACKGROUND AND PURPOSE Only a single study has demonstrated beneficial effects of intravenous tissue plasminogen activator (tPA) in stroke patients. METHODS We evaluated the clinical outcomes of the 61 patients enrolled in the Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) study who were randomized to receive intravenous tPA or placebo within 3 hours ...

متن کامل

Efficacy and safety of i.v. alteplase therapy up to 4.5 hours after acute ischemic stroke onset.

PURPOSE The efficacy and safety of i.v. alteplase up to 4.5 hours after acute ischemic stroke (AIS) onset were evaluated. SUMMARY Stroke is the leading cause of disability in the elderly, and i.v. alteplase (recombinant tissue plasminogen activator) is the only Food and Drug Administration (FDA)-approved thrombolytic agent for the treatment of AIS. Alteplase has been shown to decrease the per...

متن کامل

Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.

BACKGROUND Intravenous thrombolysis with alteplase is the only approved treatment for acute ischemic stroke, but its efficacy and safety when administered more than 3 hours after the onset of symptoms have not been established. We tested the efficacy and safety of alteplase administered between 3 and 4.5 hours after the onset of a stroke. METHODS After exclusion of patients with a brain hemor...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Stroke

سال: 2006

ISSN: 0039-2499,1524-4628

DOI: 10.1161/01.str.0000227191.01792.e3